Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

17.9K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.9K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.2K
Lineage Commitment01:21

Lineage Commitment

4.5K
Commitment is the  process whereby stem cells:
4.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

657
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
657

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026
Same author

Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.

Haematologica·2026
Same author

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

HemaSphere·2026
Same author

Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.

Leukemia & lymphoma·2026
Same author

CAR-T Cells: Current Status, Challenges, and Future Prospects.

MedComm·2026
Same author

Inhibition of SUV39H1 as a potent therapeutic target in multiple myeloma.

Haematologica·2026

Related Experiment Video

Updated: Mar 22, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K

Differential effects of lenalidomide during plasma cell differentiation.

Michel Jourdan1,2, Maïlys Cren1, Peter Schafer3

  • 1INSERM, U1040, Montpellier, France.

Oncotarget
|April 9, 2016
PubMed
Summary

Lenalidomide impacts normal plasma cell generation, particularly early stages and long-lived plasma cells. This research clarifies lenalidomide

Keywords:
IKZF1IKZF3differentiationlenalidomideplasma cell

More Related Videos

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

10.2K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

13.3K

Related Experiment Videos

Last Updated: Mar 22, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K
Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

10.2K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

13.3K

Area of Science:

  • Immunology
  • Hematology
  • Pharmacology

Background:

  • Immunomodulatory drugs like thalidomide, lenalidomide, and pomalidomide have significantly improved multiple myeloma outcomes.
  • The precise effects of these drugs on normal plasma cells, the healthy counterparts of myeloma cells, remain largely unknown.

Purpose of the Study:

  • To investigate the effects of lenalidomide on the generation and survival of normal human plasma cells using an in vitro model.
  • To elucidate the molecular mechanisms underlying lenalidomide's impact on plasma cell differentiation and transcription factor expression.

Main Methods:

  • Utilized an in vitro model of normal human plasma cell generation.
  • Assessed the impact of lenalidomide on pre-plasmablast, plasmablast, and early plasma cell production.
  • Quantified the expression levels of key transcription factors (Ikaros, Aiolos, IRF4) in response to lenalidomide treatment.
  • Evaluated the effect of lenalidomide on the generation and long-term survival of long-lived plasma cells.

Main Results:

  • Lenalidomide inhibited the generation of pre-plasmablasts and early plasma cells, with a moderate effect on plasmablast production.
  • Reduced expression of Ikaros, Aiolos, and IRF4 transcription factors was observed in lenalidomide-treated plasmablasts and early plasma cells.
  • Lenalidomide inhibited the generation of long-lived plasma cells but did not affect their survival once established.
  • Clinical data from patients showed no change in healthy bone marrow plasma cell counts after 3-18 months of lenalidomide treatment.

Conclusions:

  • Lenalidomide differentially affects normal plasma cell generation, primarily inhibiting early stages.
  • The observed effects on transcription factors suggest a mechanism not solely dependent on Ikaros or Aiolos degradation.
  • Lenalidomide's inability to impair established long-lived plasma cell survival may have implications for therapeutic resistance.
  • Further investigation is warranted to determine if lenalidomide resistance in multiple myeloma is linked to less sensitive malignant plasmablasts or long-lived plasma cells.